The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 1, 2012, Pages 13-22

  Zhu, Yuao ^a,b   Curtis, Maria ^a   Borroto Esoda, Katyna ^a  

^a GILEAD SCIENCES   (United States)

^b PHARMASSET INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; P PROTEIN, HEPATITIS B VIRUS; PHOSPHONIC ACID DERIVATIVE; POL PROTEIN;

ARTICLE; CELL MUTANT; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA REPLICATION; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NATIONAL HEALTH ORGANIZATION; NONHUMAN; PLASMID; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; QUANTITATIVE ANALYSIS; SOUTHERN BLOTTING; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS REPLICATION; WILD TYPE; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENETICS; HEPATITIS B; MUTATION; VIROLOGY;

ADENINE; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; GENOTYPE; HEP G2 CELLS; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MUTATION; PHOSPHONIC ACIDS; VIRUS REPLICATION;

EID: 84863108115     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1791     Document Type: Article

References (35)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373:582-592.
2. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
3. Carman WF, Jacyna MR, Hadziyannis S, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2:588-591.
4. Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68:8102-8110.
5. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077-4081.
6. Junker-Niepmann M, Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and suffcient for packaging of foreign RNA. EMBO J 1990; 9:3389-3396.
7. Chu C-J, Keeffe EB, Han S-H, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology 2003; 125:444-451.
8. Chu C-J, Keeffe EB, Han S-H, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003; 38:619-628.
9. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628-633.
10. Ono-Nita SK, Kato N, Shiratori Y, et al. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 1999; 103:1635-1640.
11. Ono-Nita SK, Kato N, Shiratori Y, et al. YMDD motif in hepatitis B virus DNA polymerase infuences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 1999; 29:939-945.
12. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication effcacy of lamivudine-resistant mutants. J Virol 2004; 78:8524-8535.
13. Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37:27-35.
14. Scaglioni PP, Melegari M, Wands JR. Biologic properties of hepatitis B viral genomes with mutations in the precore promoter and precore open reading frame. Virology 1997; 233:374-381.
15. Lamberts C, Nassal M, Velhagen I, Zentgraf H, Schroder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993; 67:3756-3762.
16. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol 1997; 71:345-353.
17. Guidotti LG, Matzke B, Pasquinelli C, Shoenberger JM, Rogler CE, Chisari FV. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 1996; 70:7056-7061.
18. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734.
19. Delaney WE, IV, Ray AS, Yang H, et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:2471-2477.
20. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology 2009; 49:1158-1165.
21. Ladner SK, Otto M, Barker C, et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: A novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997; 41:1715-1720.
22. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77:51-59.
23. Yamamoto T, Litwin S, Zhou T, et al. Mutations of the woodchuck hepatitis virus polymerase gene that confer resistance to lamivudine and 2′-fuoro-5-methyl-β-l-arabinofuranosyluracil. J Virol 2002; 76:1213-1223.
24. Zhu Y, Curtis M, Borroto-Esoda K. HBV DNA replication mediated by cloned patient HBV reverse transcriptase genes from HBV genotypes A-H and its use in antiviral phenotyping assays. J Virol Methods 2011; 173:340-346.
25. Yang H, Westland C, Xiong S, Delaney WE, IV. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004; 61:27-36.
26. Qi X, Xiong S, Yang H, Miller M, Delaney WE, IV. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther 2007; 12:355-362.
27. Curtis M, Zhu Y, Jackson M. Highly sensitive and accurate real-time PCR assay for hepatitis B viral load quantifcation. 17th International Conference on Antiviral Research. 2-6 May 2004, Tucson, AZ, USA. Poster 48.
28. Fung SK. Presence of rtA194T at baseline does not reduce effcacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B. 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 31 October-4 November 2008, San Francisco, CA, USA. Poster 880.
29. Margeridon-Thermet S, Shulman NS, Ahmed A, et al. Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis 2009; 199:1275-1285.
30. Snow-Lampart A, Chappell B, Curtis M, et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53:763-773.
31. Snow-Lampart A, Kitrinos KM, Chappel BJ, Myrick FT, Schwawalder JC. No resistance to tenofovir disoproxil fumarate (TDF) detected following up to 192 weeks of treatment in subjects monoinfected with chronic hepatitis B virus. Hepatology 2010; 52 Suppl 1:977A.
32. Parekh S, Zoulim F, Ahn SH, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003; 77:6601-6612.
33. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70:5845-5851.
34. Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol 1999; 73:1239-1244.
35. Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology 2002; 295:86-96.